Impact of Prior Chemotherapy (CT) and Somatostatin Analogues (SSAs) on Clinical Outcome in Well-Differentiated Pancreatic Neuroendocrine Tumors (pWDNETs) before Treatment of Everolimus (EV)
#732
Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Aim(s): To evaluate the disease control rate (DCR) at first radiologic assessment (8-12 week) defined as the proportion of best radiological response achieved in pts with CR, PR or SD, as a measure of antitumor effect of EV in pWDNETs naïve pts or progressing after CT and/or SSAs.
Materials and methods: We retrospectively analyzed 32 pWDNETs pts treated with EV, between 2009 to 2012 in our Institution.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: pusceddu s
Authors: Pusceddu S, De Braud F, Milione M, Mazzaferro V, Damato A,
Keywords: everolimus,
To read the full abstract, please log into your ENETS Member account.